GlassScriptPhysician profile
Kamal Jit Mohan
NPI 1073514022
$749.00
in general payments reported to CMS, 2019-2025
15 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $69.41 · 2023: $37.90 · 2024: $140 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $148.81 | 2019-2024 | Wegovy |
| Biosense Webster, INC. | $110.42 | 2025 | Carto 3 |
| Abbvie INC. | $99.36 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.72 | 2019 | |
| Pfizer INC. | $78.64 | 2019-2024 | |
| Glaxosmithkline, LLC. | $49.74 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $36.61 | 2019 | |
| Baxter Healthcare | $26.43 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Bioxcel Therapeutics, INC. | $19.72 | 2023 | Igalmi |
| Astrazeneca Pharmaceuticals LP | $18.18 | 2023 | Farxiga |
| Paratek Pharmaceuticals, INC. | $17.83 | 2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.68 | 2024 | Xifaxan |
| Lilly USA, LLC | $16.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.